Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up

Shang-Yin Wu1†, Yuan-Hua Wu2†, Ming-Wei Yang2, Wei-Ting Hsueh2, Jenn-Ren Hsiao3, Sen-Tien Tsai3, Kwang-Yu Chang4, Jeffrey S Chang4 and Chia-Jui Yen1*

Abstract

Background: Combined radiotherapy and chemotherapy is considered the standard of care for locally advanced nasopharyngeal carcinoma (LA-NPC) in Epstein-Barr virus infection endemic area. This study compared the long-term outcomes between LA-NPC patients treated with neoadjuvant chemotherapy followed by radiotherapy (NACT) and those treated with concurrent chemoradiotherapy (CCRT).

Methods: From 2003 to 2007, a total of 128 histopathologically proven LA-NPC patients receiving either NACT or CCRT were consecutively enrolled at the National Cheng Kung University Hospital in Taiwan. NACT consisted of 3-week cycles of mitomycin, epirubicin, and cisplatin on day 1 and fluorouracil and leucovorin on day 8 (MEPFL) or weekly alternated cisplatin on day 1 and fluorouracil and leucovorin on day 8 (P-FL). CCRT comprised 3-week cycles of cisplatin (Cis 100) or 4-week cycles of cisplatin and fluorouracil (PF4). The first failure site, disease free survival (DFS), overall survival (OS), and other prognostic factors were analyzed.

Results: Thirty-eight patients (30%) received NACT. Median follow-up duration was 53 months. More patients with advanced nodal disease (N2-N3) (86.8% vs 67.8%, \( p = 0.029 \)) and advanced clinical stage (stage IVA-IVB) enrolled in the NACT group (55.2% vs 26.7%, \( p = 0.002 \)). For NACT, both MEPFL and P-FL had similar 5-year DFS and OS (52.9% vs 50%, \( p = 0.860 \) and 73.5% vs 62.5%, \( p = 0.342 \), respectively). For CCRT, both PF4 and Cis 100 had similar 5-year DFS and OS (62.8% vs 69.6%, \( p = 0.49 \) and 72.9% vs 73.9%, \( p = 0.72 \), respectively). Compared to CCRT, NACT had similar 5-year DFS and OS (51.5% vs 65.1%, \( p = 0.28 \) and 71.7% vs 74.3%, \( p = 0.91 \), respectively). Among patients who were recurrence-free in the first 2 years after treatment, those treated with NACT experienced poorer locoregional control compared to those treated with CCRT (Hazard ratio =2.57, 95% confidence interval: 1.02 to 6.47, \( p = 0.046 \)).

(Continued on next page)
Comparison of both CCRT and NACT were similarly efficacious treatment strategies in terms of long-term disease control and survival probability. Close locoregional follow-up is recommended for patients receiving NACT, because these patients are more prone to develop locoregional failure than patients receiving CCRT.

**Keywords:** Neoadjuvant chemotherapy, Concurrent chemoradiation, Nasopharyngeal carcinoma, Outcome

**Methods**

Between 2003 and 2007, patients with pathologically confirmed, previously untreated stage IIB to stage IVB NPC according to the 2002 American Joint Committee on Staging of Cancer classification [15], who received study-defined neoadjuvant chemotherapy as well as who received concurrent chemoradiotherapy in the National Cheng Kung University Hospital (NCKUH) in Tainan, Taiwan were consecutively enrolled. Treatment decisions were made by an institutional tumor board consisted of otolaryngologists, medical oncologists and radiation oncologists. Either NACT or CCRT was an accepted treatment option during that period.

Pretreatment evaluation for eligible subjects included a general physical examination, fiberoptic endoscopy, contrast-enhanced computed tomography (CT) and/or magnetic resonance imaging (MRI) of the nasopharynx and neck, chest x-ray, hepatic ultrasonography, and radionuclide bone scan.

In general, we followed the criteria reported by Lin et al. [14] to select patient to receive NACT: (1) neck nodal size >6 cm; (2) supraclavicular node metastasis; (3) skull base destruction/intracranial invasion, and (4) multiple neck nodes metastasis with one of nodal size >4 cm. In addition, if a patient could not accept a delay in radiation simulation, we also assigned him/her to receive NACT.

To be eligible, all patients had to receive study-defined chemotherapy regimen with no distant metastasis and no concurrent malignancies. Patients who had no subsequent clinical follow-up data, did not receive tumor board-defined treatment options or died during chemotherapy and/or radiotherapy treatment period were excluded from the current study.

The study was approved by the Institutional Review Board of National Cheng Kung University Hospital and preceded according to the Helsinki Declaration.
Treatment

For patients receiving NACT, the study-defined neoadjuvant chemotherapy consisted of MEPFL regimen (mitomycin 8 mg/m², epirubicin 60 mg/m², and cisplatin 60 mg/m² on day 1 and 5-fluorouracil [5-FU] 450 mg/m² plus leucovorin 30 mg/m² on day 8, 3-week cycle for 3 cycles) or weekly P-FL regimen (cisplatin 60 mg/m² 3-h infusion alternating with 5-FU 2500 mg/m² plus leucovorin 250 mg/m² continuous infusion for 24 h weekly for a total of 10 weeks) then followed by radiotherapy alone as defined by previous studies [13,14].

For patients receiving CCRT, we followed the protocol of Lin et al. (cisplatin 20 mg/m²/day plus fluorouracil 400 mg/m²/day by 96-hour continuous infusion during weeks 1 and 5 of radiotherapy; PF4 regimen) or Al-Sarraf M et al. (cisplatin 100 mg/m² on day 1, 22, and 43 during radiotherapy; Cis 100 regimen) [10,16].

Chemotherapy modification was permitted at the discretion of the primary treating physician when patients experienced grade 3 toxicity and the modification was guided by the designs of the original trials.

Radiotherapy

Intensity Modulated Radiotherapy (IMRT; Clinac iX accelerator, Varian) was equipped in our hospital in 2006. All patients treated after May 2006 used IMRT technique except one patient who received radiosurgery boost. In the 2D method, we used bilaterally opposed fields with a matched lower anterior neck field first. The bilateral opposing fields were then coned down to the high-risk regions that included nasopharynx after 43.2 Gy to avoid spinal cord damage. The posterior neck node regions were boosted with 9-12 MeV electron beam. Nasopharyngeal tumor and gross nodes were boosted by 3D conformal RT or a frameless stereotactic body radiation therapy (SBRT; Cyberknife) to the planned dose [17].

Among patients receiving IMRT, the inverse planning software (Eclipse treatment planning system, Varian) was used. The high-risk clinical target volume (CTV) covered the entire nasopharynx, tumor invasion areas, and gross nodes. The intermediate-CTV included the suspected nodes plus the involving neck levels. The low-risk CTV included other lower risk lymphatic regions for occult micrometastases. The low neck lymphatic regions were treated with the same IMRT plan. Planning target volumes (PTVs) were created by automated expansion of 3 to 5 mm of all CTVs to account for setup error. Normal structures, including the parotid glands, spinal cord, brain stem, optic nerves, and optic chiasm were also contoured on the treatment plan.

Assessment and follow-up

All patients had regular follow-up with radiation oncologists at the outpatient clinic. Patients received regular clinical examinations every 1–3 months in the first year after the completion of therapy, every 3 months during the second and third years, and then every 4–6 months thereafter. Regular follow-up MRI was performed every 3-6 months after the completion of radiation therapy and then every 6-12 months thereafter if no gross tumor recurrence was noted clinically.

Statistical analysis

We collected the patients’ demographic data, including gender and age, histology type, and stage as well as chemotherapy regimen and given cycles, radiotherapy dose and elapsed days. The location of the first clinical relapse was recorded and classified as locoregional failure if the first relapse site was nasopharynx or neck nodal area and as distant failure if relapse site was beyond the above-mentioned areas. The duration of disease-free survival (DFS), time to locoregional failure (TTLF) and time to distant failure (TTDF) were calculated from Day 1 of the treatment until documented treatment failure, death from any cause or the date of last follow-up, whichever came first. The duration of overall survival (OS) was measured from Day 1 of the treatment until death or the date of last follow-up.

Statistical analyses were performed using SPSS statistical program (SPSS for Windows, release 17.0; SPSS, Chicago, IL, USA) and SAS 9.2 (Cary, NC, USA). The Pearson χ² test or Fisher’s exact test (if the expected number was less than five in at least one cell) for comparison of categorical variables and independent t test for comparison of continuous variables were applied. To evaluate the survival of the patients, we used the Kaplan-Meier test to construct survival curves, which were compared using log-rank tests. Kaplan-Meier survival curves were drawn using GraphPad Prism 4 (La Jolla, CA, USA). Hazard ratio (HR) and the associated 95% confidence interval (CI) were calculated using Cox regression model. For all statistical analyses, a two-sided P value <0.05 was considered statistically significant.

Results

Patient characteristics

From 2003 to 2007, a total of 128 eligible patients were consecutively enrolled. The median age was 48 years (range: 16-81 years). Thirty-eight patients (30%) received NACT and 90 patients received CCRT. Patients’ disease characteristics and demographics were well-balanced in each group except more patients with advanced nodal disease (N2-N3) (86.8% vs 67.8%, p =0.029) and advanced clinical stage (stage IVA-IVB) enrolled in the NACT group (55.2% vs 26.7%, p =0.002) (Table 1).

Treatment administration and compliance

In the NACT group, six of eight patients (75%) completed the planned three-cycle MEPFL and twenty-nine
of thirty patients (96.7%) finished the ten-week P-FL neoadjuvant chemotherapy, which were comparable to those reported by previous studies (90% for MEPFL reported by Hong et al. [13] and 93% for P-FL reported by Lin et al. [14]).

In the CCRT group, sixty four of sixty-six (97%) and twenty of twenty-four patients (83.3%) received concurrent chemoradiotherapy with PF4 for two times and Cis 100 every three weeks, respectively, which were similar to those previously reported (93.6% for PF4 reported by Lin et al. [16] and 62.8% for Cis 100 reported by Al-Sarraf M el al. [10]).

A total of 61 patients received the traditional 2D radiotherapy followed by conformal RT or radiosurgery boost, while 67 patients received a full course of IMRT. As for the radiation compliance, the median RT dose and the median duration of RT were no significantly different between the NACT group and the CCRT group ($p=0.123$ and 0.772 respectively) (Table 2) and none of the patients died within 90 days after radiotherapy completed.

Efficacy
After a median follow-up of 53 months (range: 7 to 101 months), twenty-one (16.4%) and twenty-two (17.2%) patients developed locoregional and distant failure as the first failure site, respectively. And for non-recurrent subjects, the median follow-up time was 59 months (range: 41 to 101 months). The frequency, site of first recurrence and the first salvage treatment modality for locoregional recurrence in each treatment group are summarized in Table 3. Notably, compared with the CCRT group, the locoregional control appeared poorer for the NACT group (23.7% vs 13.3%).

For the 38 patients in the NACT group, the 3-year and 5-year DFS rate were 60.5% and 51.5%, respectively, and the 3-year and 5-year OS rate were 86.8% and 71.7% respectively. Compared with patients who received MEPFL regimen, patients who received P-FL regimen had similar 5-year DFS and OS (52.9% vs 50%, $p=0.860$ and 73.5% vs 62.5%, $p=0.342$, respectively).

Table 1 Patient demographics and disease characteristics

| Characteristics       | CCRT group (n = 90) | NACT group (n = 38) | P-value |
|-----------------------|---------------------|---------------------|---------|
| Age, years            | No. %               | No. %               |         |
| Range                 | 15.7 - 81.5         | 22.9 - 73.0         | 0.95    |
| Median                | 48.2                | 48.2                |         |
| Mean                  | 47.9                | 47.8                |         |
| Gender                | Male 73 (81.1)      | Male 28 (73.7)      |         |
| Female 17 (18.9)      | Female 10 (26.3)    |                      |         |
| WHO Classification    | Type I 4 (4.4)      | Type I 2 (5.3)      | 0.941   |
| Type II               | 31 (34.4)           | 12 (31.6)           |         |
| Type III              | 55 (61.1)           | 24 (63.2)           |         |
| T stage               | T1 to T2 56 (62.2)  | T1 to T2 50         | 0.200   |
| T3 to T4              | 34 (37.8)           | T3 to T4 50         |         |
| N stage               | N0 to N1 29 (32.2)  | N0 to N1 13.2       | 0.029   |
| N2 to N3              | 61 (67.8)           | N2 to N3 86.8       |         |
| Overall Stage         | IIB-III 66 (73.3)   | IIB-III 44.8        | 0.002   |
| IVA-IVB               | 24 (26.7)           | IVA-IVB 55.2        |         |

CCRT, concurrent chemoradiotherapy; NACT, neoadjuvant chemotherapy followed by radiotherapy; WHO, World Health Organization.

Table 2 Compliance with radiotherapy

| RT Technique | CCRT group (n = 90) | NACT group (n = 38) | P-value |
|--------------|---------------------|---------------------|---------|
| 2D, n (%)    | 44 (48.9)           | 17 (44.7)           | 0.667   |
| IMRT, n (%)  | 46 (51.1)           | 21 (55.3)           |         |

| RT Compliance | CCRT group (n = 90) | NACT group (n = 38) | P-value |
|---------------|---------------------|---------------------|---------|
| Median dose RT, cGy (range) | 7380 (6020 - 7800) | 7200 (6840 - 7720) | 0.123   |
| Median duration of RT, Days (range) | 58 (51 - 84) | 57 (48 - 81) | 0.772   |

Table 3 Frequency, site of first recurrence and first salvage treatment modality for locoregional recurrence

| First failure site | CCRT group (n = 90) | NACT group (n = 38) | P-value |
|--------------------|---------------------|---------------------|---------|
| Locoregional       | 12 (13.3)           | 9 (23.7)            |         |
| Distant            | 14a                 | 8 (21.1)            |         |
| Lung               | 4                    | 4                   |         |
| Bone               | 6                    | 2                   |         |
| Liver              | 5                    | 1                   |         |
| Others             | 2b                   | 1c                  |         |

| First treatment modality for locoregional failure | CCRT group (n = 90) | NACT group (n = 38) | P-value |
|--------------------------------------------------|---------------------|---------------------|---------|
| Surgery                                         | 1                   |                     | -       |
| Re-irradiation                                  | 1                   | 6 (66.7)            |         |
| Re-CCRT                                         | 5                   | 3                   | 33.3    |
| Chemotherapy                                    | 5                   | 41.7                |         |

aOne patient had bone and lung metastases concurrently and the other one had bone, liver and lung metastases simultaneously. bOne patient developed mediastinal lymph node metastases and the other one developed para-aortic lymph node metastases. cThe subject developed axillary lymph node metastases.
For the 90 patients in the CCRT group, the 3-year and 5-year DFS rate were 72.2% and 65.1%, respectively, and the 3-year and 5-year OS rate were 83.3% and 74.3%, respectively. Compared with patients who received Cis 100 regimen, patients who received PF4 regimen had similar 5-year DFS and OS without statistical difference (62.8% vs 69.6%, \( p = 0.49 \) and 72.9% vs 73.9%, \( p = 0.72 \), respectively).

The 5-year DFS rate in the NACT group and the CCRT group was 51.5% and 65.1% respectively (\( p = 0.28 \)). Advanced clinical T stage (T3-4) and advanced clinical overall stage (stage IVA-IVB) were associated with a shorter disease free survival (HR = 2.19, 95% CI: 1.24 to 3.85, \( p = 0.007 \) and HR = 2.7, 95% CI: 1.54 to 4.74, \( p = 0.0006 \), respectively). The DFS was not influenced by other clinical parameters, including gender (\( p = 0.33 \)), WHO histology classification (\( p = 0.72 \)), or nodal status (\( p = 0.35 \)) (Table 4). NPC with advanced clinical stage (stage IVA-IVB) had poor locoregional control (HR = 2.84, 95% CI: 1.19 to 6.77, \( p = 0.002 \)) and those receiving NACT tended to have poor locoregional control (HR = 1.75, 95% CI: 0.74 to 4.16, \( p = 0.20 \)). Advanced clinical stage (stage IVA-IVB) was the only clinical parameter predicting poor distant control (HR = 2.62, 95% CI: 1.13 to 6.08, \( p = 0.02 \)) (Table 5).

Notably, the Kaplan-Meier DFS curves of the NACT group and the CCRT group started to separate at 2 years after treatment (Figure 1A). According to past experience, most NPC patients suffered from disease recurrence in the first 2-3 years while completing radical therapy for advanced disease control [13,18]. When we only considered patients who remained disease-free in the first 2 years for further analysis, compared to those who received CCRT, patients who received NACT had a higher risk for recurrence (HR = 2.57, 95% CI:1.02 to 6.47, \( p = 0.046 \) (Figure 1C). No other clinical parameters, such as gender (\( p = 0.26 \)), histology classification (\( p = 0.23 \)), clinical T stage (\( p = 0.07 \)), clinical nodal stage (\( p = 0.44 \)) and clinical stage (\( p = 0.49 \)), had a significant influence on late disease recurrence.

The 5-year TTLF rate was 85.2% for CCRT and 74.5% for NACT (\( p = 0.20 \)) and the 5-year TTDF rate was 83.1% for CCRT and 76.4% for NACT (\( p = 0.56 \)). The Kaplan-Meier curve did not separate till 2 years in TTLF analysis (Figure 2A) but not in TTDF analysis (Figure 2B). When we re-analyzed patients who remained disease-free in first 2 years, patients who received NACT had a higher risk for developing locoregional failure (HR = 6.31, 95% CI: 1.22 to 32.59, \( p = 0.03 \)) but not distant failure (HR = 1.87, 95% CI: 0.50 to 6.96, \( p = 0.35 \)). No other clinical parameters, such as gender, histology classification, clinical T stage, clinical nodal stage and clinical stage had a significant influence on late locoregional failure or distant failure (Table 6).

### Table 4 Univariate Cox regression analysis for disease free survival and overall survival

|                | DFS | OS |
|----------------|-----|----|
| **Event**      |     |    |
| Male (n = 101) | 41  | 33 |
| Female (n = 27)| 8   | 3  |
| **WHO Classification** |     |    |
| Type I (n = 6) | 3   | 1  |
| Type II (n = 43)| 17  | 12 |
| Type III (n = 79)| 29  | 23 |
| **cT**         |     |    |
| T1-2 (n = 75)  | 21  | 13 |
| T3-4 (n = 53)  | 28  | 23 |
| **cN**         |     |    |
| N0-1 (n = 34)  | 11  | 10 |
| N2-3 (n = 94)  | 38  | 26 |
| **Stage**      |     |    |
| III/IV (n = 83)| 23  | 15 |
| IVA/IVB (n = 45)| 26  | 21 |
| **Treatment**  |     |    |
| CCRT group (n = 90)| 31  | 25 |
| NACT group (n = 38)| 18  | 11 |

DFS, disease free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.
Thirty-six of 128 patients (28.1%) died during the study period which consisted of 25 in the CCRT group and 11 in the NACT group. The 5-year OS rate in NACT group and CCRT group was 71.7% and 74.3%, respectively ($p = 0.91$). Similar to DFS, only advanced T stage (HR = 2.9, 95% CI: 1.47-5.73, $P = 0.002$) and advanced clinical stage (HR = 3.0, 95% CI: 1.54-5.83, $P = 0.001$) had poor overall survival (Table 4).

Although the NACT group tended to have poorer locoregional control than the CCRT group, more patients survived after salvage therapy in the NACT group (five patients survived among the nine locoregional failure patients) than in the CCRT group (three patients survived among the twelve locoregional failure patients), which resulted in a similar long-term OS in both treatment groups.

CCRT is considered the standard of care for locally advanced NPC but the relative benefit of this approach may be less in Epstein-Barr virus infection endemic area [8,19]. NACT showed promising result in terms of overall survival and treatment tolerability in the NPC-endemic area and this treatment strategy seems to be another reasonable option at least in the NPC-endemic area [13,14,20]. For locally advanced NPC, only limited information regarding the comparison between NACT and CCRT in terms of DFS and OS has been reported and no information on long-term DFS and OS is available.

To the best of our knowledge, only Xu et al. and Komatsu et al. have ever addressed this issue [21,22]. In a preliminary report, Xu and colleagues reported a relatively short-term 3-year follow-up result of a phase III randomized study comparing NACT and CCRT for locally advanced NPC [22]. After a median follow-up of 38 months, the 3-year OS was 95.9% vs. 94.5% ($p = 0.54$).

**Table 5 Univariate Cox regression analysis for locoregional failure and distant failure**

|                      | Locoregional failure | Distant failure |
|----------------------|----------------------|-----------------|
|                      | Event | HR  | 95% CI  | $P$-value | Event | HR  | 95% CI  | $P$-value |
| Gender               |       |     |         |           |       |     |         |           |
| Male (n = 101)       | 16    | 1.00 |         |           | 20    | 1.00 |         |           |
| Female (n = 27)      | 5     | 1.11 | 0.41-3.04 | 0.83 | 2     | 0.36 | 0.08-1.53 | 0.16 |
| WHO Classification   |       |     |         |           |       |     |         |           |
| Type I (n = 6)       | 1     | 1.00 |         |           | 1     | 1.00 |         |           |
| Type II (n = 43)     | 8     | 0.98 | 0.12-7.82 | 0.98 | 6     | 0.75 | 0.09-6.21 | 0.79 |
| Type III (n = 79)    | 12    | 0.83 | 0.11-6.39 | 0.86 | 15    | 1.05 | 0.14-7.94 | 0.96 |
| cT                   |       |     |         |           |       |     |         |           |
| T1-2 (n = 75)        | 9     | 1.00 |         |           | 10    | 1.00 |         |           |
| T3-4 (n = 53)        | 12    | 2.11 | 0.89-5.02 | 0.09 | 12    | 1.90 | 0.82-4.39 | 0.14 |
| cN                   |       |     |         |           |       |     |         |           |
| N0-1 (n = 34)        | 5     | 1.00 |         |           | 3     | 1.00 |         |           |
| N2-3 (n = 94)        | 16    | 1.20 | 0.44-3.29 | 0.72 | 19    | 2.43 | 0.72-8.24 | 0.15 |
| Stage                |       |     |         |           |       |     |         |           |
| III/II (n = 83)      | 9     | 1.00 |         |           | 10    | 1.00 |         |           |
| IVA/IVB (n = 45)     | 12    | 2.84 | 1.19-6.77 | 0.02 | 12    | 2.62 | 1.13-6.08 | 0.02 |
| Treatment            |       |     |         |           |       |     |         |           |
| CCRT group (n = 90)  | 12    | 1.00 |         |           | 14    | 1.00 |         |           |
| NACT group (n = 38)  | 9     | 1.75 | 0.74-4.16 | 0.20 | 8     | 1.29 | 0.54-3.08 | 0.56 |

**Discussion**

For locally advanced NPC, the present study demonstrated that both NACT and CCRT resulted in similar outcomes in terms of 5-year DFS and OS, despite that more patients with advanced nodal disease (N2-N3, 86.8% vs 67.8%, $p = 0.029$) and advanced overall clinical stage (stage IVA-IVB, 55.2% vs 26.7%, $p = 0.002$) enrolled in NACT group. In addition, our study also showed that for patients who were disease-free in the first two years after the completion of treatment, those who received NACT experienced poorer late locoregional control (HR = 2.57, 95% CI: 1.02 to 6.47, $p = 0.046$) (Figure 1C). Despite that NACT tended to have poorer locoregional control than CCRT, more patients survived after salvage therapy in the NACT group (five patients survived among the nine locoregional failure patients) than in the CCRT group (three patients survived among the twelve locoregional failure patients), which resulted in a similar long-term OS in both treatment groups.

To the best of our knowledge, only Xu et al. and Komatsu et al. have ever addressed this issue [21,22]. In a preliminary report, Xu and colleagues reported a relatively short-term 3-year follow-up result of a phase III randomized study comparing NACT and CCRT for locally advanced NPC [22]. After a median follow-up of 38 months, the 3-year OS was 95.9% vs. 94.5% ($p = 0.54$).
Figure 1 Kaplan-Meier curves of disease free survival and overall survival. Kaplan-Meier curves of disease free survival (A) and overall survival (B) for patients in NACT group (red) in comparison with CCRT group (black). Patients without recurrence or death in first 2 years were further analyzed and disease free survival (C) and overall survival (D) curve as illustrated.

Figure 2 Kaplan-Meier curves of time to locoregional failure and time to distant failure. Kaplan-Meier curves of time to locoregional failure (A) and time to distant failure (B) for patients in NACT group (red) in comparison with CCRT group (black). Patients without recurrence or death in first 2 years were further analyzed and time to locoregional failure (C) and time to distant failure (D) curve as illustrated.
in NACT and CCRT, respectively, which is better than our 3-year OS result of 83.3% vs. 86.8% (p = 0.91). This may be partly due to the fact that 45 of 128 (35%) in our cohort were stage IVA-IVB disease, in contrast to the 85 of 338 (25%) in the study by Xu et al. In addition, 67% of the study population in Xu et al. trial received the planned adjuvant chemotherapy, while none of our study patients received the planned adjuvant chemotherapy. In the DFS analysis by Xu et al., the 3-year DFS in the NACT group was inferior than that in the CCRT group (78.5% vs. 82.5%, p = 0.16) and the Kaplan-Meier curves of the NACT group and the CCRT group separated after 16 months, which was consistent with our finding. Because most NPC patients suffered from disease recurrence during the first 2-3 years while completing radical therapy for advanced disease control [13,18], we further analyzed patients who remained disease-free in the first two years after completion of treatment, and found that patients who received NACT experienced poorer late locoregional control (HR = 2.57, 95% CI: 1.02 to 6.47, p = 0.046) compared to those who received CCRT (Figure 1C).

Komatsu et al. reported a relatively small series (N = 46) of advanced NPC patients receiving either CCRT or NACT with a long-term follow-up (median 51.7 months) [21]. They reported that the 5-year disease specific survival in NACT and CCRT was 67.3% and 60.1%, respectively, which is similar to our finding (in our study, the 5-year rate was 71.7% vs. 74.3%). In addition, the authors also noted that the CCRT group showed less locoregional failure than in the NACT group (12% vs. 19%) and suggested CCRT could provide better locoregional control. Our result is consistent with that reported by Komatsu et al. (Figures 1C and 2C) and we further demonstrated that among patients who remained disease-free in the first two years after completion of treatment, those who received NACT experienced poorer late locoregional control than those who received CCRT (Table 6).

Although this is the first observational study to address NACT and CCRT efficacy for locally advanced NPC with a relatively large number of patients (N = 128) and a long-term follow-up (median follow-up = 53 months) in a NPC-endemic area, several limitations need to be mentioned. First, the study design was retrospective and in order to minimize selection bias, we included all consecutively-enrolled eligible patients in our institute during the study period for the current analysis. Second, we adopted two different chemotherapy regimens in both the NACT and the CCRT group. In the NACT group, we used P-FL or MEP-FL as the NACT regimen and they had a similar drug administration rate, compliance rate, DFS, and OS with each other and with those reported by

|                      | Locoregional failure |                         | Distant failure |                         |
|----------------------|----------------------|--------------------------|----------------|--------------------------|
|                      | Event | HR     | 95% CI | P Value | Event | HR     | 95% CI | P Value |
| Gender               |        |        |        |         |        |        |        |         |
| Male (n = 76)        | 5      | 1.00   |        |         | 9      | 1.00   |        |         |
| Female (n = 21)      | 2      | 1.41   | 0.27-7.29 | 0.68 | 0 | – | – | – |
| WHO Classification   |        |        |        |         |        |        |        |         |
| Type III (n = 59)    | 2      | 1.00   |        |         | 6      | 1.00   |        |         |
| Type II (n = 35)     | 5      | 4.39   | 0.85-22.62 | 0.08 | 3 | 0.83 | 0.21-3.33 | 0.79 |
| Type I (n = 3)       | 0      | –      | –      | –       | 0      | –      | –      | –       |
| cT                   |        |        |        |         |        |        |        |         |
| T1-2 (n = 62)        | 3      | 1.00   |        |         | 4      | 1.00   |        |         |
| T3-4 (n = 35)        | 4      | 2.47   | 0.55-11.05 | 0.24 | 5 | 2.25 | 0.61-8.41 | 0.22 |
| cN                   |        |        |        |         |        |        |        |         |
| N0-1 (n = 27)        | 1      | 1.00   |        |         | 2      | 1.00   |        |         |
| N2-3 (n = 70)        | 6      | 2.64   | 0.32-22.02 | 0.37 | 7 | 1.49 | 0.31-7.19 | 0.62 |
| Stage                |        |        |        |         |        |        |        |         |
| IIB/III (n = 72)     | 4      | 1.00   |        |         | 7      | 1.00   |        |         |
| IVA/IVB (n = 25)     | 3      | 2.31   | 0.52-10.35 | 0.27 | 2 | 0.79 | 0.16-3.82 | 0.77 |
| Treatment            |        |        |        |         |        |        |        |         |
| CCRT group (n = 68)  | 2      | 1.00   |        |         | 5      | 1.00   |        |         |
| NACT group (n = 29)  | 5      | 6.31   | 1.22-32.59 | 0.03 | 4 | 1.87 | 0.50-6.96 | 0.35 |

Table 6 Univariate Cox regression analysis for locoregional failure and distant failure for subjects without recurrence or death in the first two years.
previous studies. Thus, we combined these two different subgroups together as NACT for further analysis and we did the same thing for the CCRT group. Third, we reported the long-term follow-up outcome without reporting the post-treatment response because the aim of this study was to determine the long-term efficacy of NACT and CCRT and not the treatment response. Besides, the slowing regressing tumor or a truly residual tumor in post-treatment locally advanced NPC patients may be difficult to differentiate without surgical confirmation [1,13] and not all of the suspicious patients in our cohort received post-treatment nasopharyngeal biopsy to have a complete report of the treatment response. Finally, we did not report treatment-related toxicities in this retrospective study because the physicians only recorded the most significant adverse effect in daily practice instead of recording all adverse effects as required in a clinical trial and this could have resulted in the underestimation of the minor significant adverse effects.

Conclusions

In conclusion, our study demonstrated that both CCRT and NACT are similarly efficacious treatment strategies in terms of long-term DFS and OS for locally advanced NPC in Taiwan and possibly in the other Epstein-Barr viral infection endemic areas. For patients receiving NACT, a long-term follow-up is recommended because these patients are more prone to develop locoregional failure than patients receiving CCRT. It seems that neo-adjuvant chemotherapy followed by concurrent chemoradiation therapy can provide the best survival benefit for LA-NPC but several studies have generated conflicting results and this issue needs further investigation with a proper study design and patient selection [20,24,25]. The long-term follow-up result from the phase III study of Xu et al. [22] will provide more direct evidence and knowledge about the role of NACT for LA-NPC in NPC-endemic area.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CJY conceived and designed the study. MWY, WTH, STT, KYC, JRH contributed materials. CJY, YHW, SYW performed the experiment. JSC, SYW, CJY analyzed and interpreted the data. SYW, YHW, JSC wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgement

We thank all physicians who participated in the institutional head and neck cancer tumor board for their dedication in patient care and Ms. Chen-Lin Lin, the head and neck cancer case manager of Cancer Center, National Cheng Kung University Hospital, for her assistance in patient data collection.

Author details

1Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan. 2Department of Radiation Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 3Department of Otorhinolaryngology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 4National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.

Received: 23 April 2014 Accepted: 9 October 2014
Published: 28 October 2014

Reference

1. Wei WI, Sham JST. Nasopharyngeal carcinoma. Lancet 2005, 365(9476):2041–2054.
2. Rottey S, Madani I, Deron P, Van Belle S. Modern treatment for nasopharyngeal carcinoma: current status and prospects. Curr Opin Oncol 2011, 23(3):254–258.
3. Nicholls J. Nasopharyngeal carcinoma: classification and histological appearance. Adv Anat Path 1997, 4:71–84.
4. Gearing BA, Sanguineti G, Tucker SL, Garden AS, Ang KK, Morrison WH, Peters LJ. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol 1997, 43(1):63–61.
5. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004, 22(22):4604–4612.
6. O’Sullivan B. Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007, 69(2):S118–121.
7. Bajaj B, Audhy H, Bouthous J, Chan AT, Onat H, Chu AT, Kwong DL, Al-Sarraf M, Chi KH, Hayeyma M, Leung SF, Thephemongkol K, Pignon JP, MAC-NPC Collaborative Group: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006, 64(1):47–56.
8. Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, Guo Y, Huang YJ, Guan ZZ. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 2010, 10:558.
9. Lee AK, Tung SY, Chua DT, Ngan RK, Chappell R, Tung R, Shiu L, Ng WT, Sze WK, Au GK, Law SC, O’Sullivan B, Yau TK, Leung TW, Au JS, Sze WM, Choi CW, Fung KK, Lau JT, Lau WH. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010, 102(13):1188–1198.
10. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Voutetakis A, Adams G, Sahr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16(4):1310–1317.
11. Chua DTT, Ma J, Sham JST, Mai HQ, Choy DT, Hong MH, Lu TX, Min HQ. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. J Clin Oncol 2005, 23(6):1119–1124.
12. Ma BS, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 2005, 103(1):22–31.
13. Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, Wang CC, Chung NN, Lui LT. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001, 19(23):4305–4313.
14. Lin JC, Jan JS, Hsu CY, Jiang RS, Wang YW. Outpatient weekly neo-adjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates. Br J Cancer 2003, 88(2):187–194.
15. Greenie F, Page D, Fleming I, Fritz A, Balch CM, Haller DG, Morrow M: AJCC Cancer Staging Manual. 6th edition. Berlin, Heidelberg, New York, London, París, Tokyo and Hong Kong: Springer-Verlag; 2002.
16. Lin JC. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003, 21(4):631–637.
17. Chen HH, Tsai ST, Wang MS, Wu YH, Hsueh WT, Wang MW, Yeh IC, Lin JC: Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 66(5):1408–1414.

18. Lee AW, Foo W, Law SC, Poon YF, Sze WM, O SK, Tung SY, Chappell R, Lau WH, Ho JH: Recurrent nasopharyngeal carcinoma: the puzzles of long latency. Int J Radiat Oncol Biol Phys 1999, 44(1):149–156.

19. Chan AT, Gregoire V, Lefebvre JL, Licitra L, Felip E, Group E-E-EGW: Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v187–189.

20. Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT: Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009, 27(2):242–249.

21. Komatsu M, Tsukuda M, Matsuda H, Horitchi C, Taguch T, Takahashi M, Nishimura G, Mori M, Niho T, Ishitoya J, Sakuma Y, Hirama M, Shiono O: Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma. Anticancer Res 2012, 32(2):681–686.

22. Xu T, Hu C, Zhu G, He X, Wu Y, Ying H: Preliminary results of a phase III randomized study comparing chemotherapy neoadjuvantly or concurrently with radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Med Oncol 2012, 29(1):272–278.

23. Kwong DT, Nicholls J, Wei W, Chua DT, Sham JS, Yuen PW, Cheng AC, Wan KY, Kwong PW, Choy DT: The time course of histologic remission after treatment of patients with nasopharyngeal carcinoma. Cancer 1999, 85(7):1446–1453.

24. Fountzilas G, Giuleanu E, Bobos M, Kalogeira-Fountzila A, Elfeheraki AG, Karayannopoulos G, Zaramboukas T, Nikolau A, Markou K, Resiga L, Dionysopoulou D, Samantas E, Athanassiou H, Misailidou D, Skarlos D, Giuleanu T: Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol 2012, 23(2):427–435.

25. Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, Deng MQ, Qiu F, Cao SM, Guo Y, Zhang L, Li NW, Sun R, Chen QY, Luo DH, Hua YJ, Mai HQ, Hong MH: A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2012, 48(10):1038–1044.

doi:10.1186/1471-2407-14-787
Cite this article as: Wu et al.: Comparison of concurrent chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up. BMC Cancer 2014 14:787.